Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14035499 | 1.00 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL27782829 | 0.86 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL9816200 | 0.86 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL12806778 | 0.83 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL8507420 | 0.83 | OPRL1 (0.63) | SLC6A4SLC6A2OPRL1CYP1A2CYP2D6 | |
| SCHEMBL1205831 | 0.83 | OPRL1 (0.63) | SLC6A4SLC6A2OPRL1CYP1A2CYP2D6 | |
| SCHEMBL3583059 | 0.83 | OPRL1 (0.63) | SLC6A4SLC6A2OPRL1CYP1A2CYP2D6 | |
| SCHEMBL23780908 | 0.83 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL30330305 | 0.83 | CYP2D6 (0.62) | SLC6A4SLC6A2SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL12806751 | 0.82 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0141884-B1 | NOVEL PHENYLPIPERAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THERAPEUTIC COMPOSITIONS CONTAINING THEM | JUSTE, S.A. QUIMICO-FARMACEUTICA (ES) | 1988-07-20 | — | — | EP | claimed |
| EP-0141884-A1 | Novel phenylpiperazine derivatives, process for preparing them and therapeutic compositions containing them | JUSTE, S.A. QUIMICO-FARMACEUTICA (ES) | 1985-05-22 | — | — | EP | claimed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| EP-0141884-B1 | NOVEL PHENYLPIPERAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THERAPEUTIC COMPOSITIONS CONTAINING THEM | JUSTE, S.A. QUIMICO-FARMACEUTICA (ES) | 1988-07-20 | — | — | EP | disclosed |
| EP-0141884-A1 | Novel phenylpiperazine derivatives, process for preparing them and therapeutic compositions containing them | JUSTE, S.A. QUIMICO-FARMACEUTICA (ES) | 1985-05-22 | — | — | EP | disclosed |
| US-4096260-A | Novel indoles | ROUSSEL UCLAF (FR) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | EPHB4, EPHB1, NME2 | SLC6A4 2437/4885SLC6A2 3334/4885SLC6A3 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.